Fig. 7.

Effect of NADPH supplementation or CD38 inhibition on recovery of contractile function and infarction in WT and eNOS^−/− hearts. Studies were performed on isolated hearts that were pretreated with liposomal NADPH (N) or the CD38 inhibitor (αNAD) and then subjected to I/R. Results are shown for LVDP, maximum derivative of LVDP versus time (dP/dt), LVEDP, and infarct size as percentage of the LV. In WT hearts, either NADPH or α-NAD treatment enhanced the recovery of contractile function, with higher LVDP and dP/dt seen with lower LVEDP; whereas in eNOS^−/− no significant changes were seen with either treatment. Liposomal NADPH decreased infarct size only in WT but not in eNOS^−/− hearts. α-NAD decreased infarct size in WT with only a small effect in eNOS^−/− hearts that did not reach significance. **P < 0.01 and *P < 0.05 versus respective untreated group (mean ± SEM; n = 7–9).